Confirmed objective responses

Response1 L (n = 62)2 L (n = 20)
Best overall response, n (%)
 Complete response1 (1.6)0
 Partial response9 (14.5)2 (10.0)
 Stable disease38 (61.3)13 (65.0)
 Progressive disease11 (17.7)4 (20.0)
 Not evaluable3 (4.8)a1 (5.0)b
Objective response rate (95% CI), %16.1 (8.0–27.7)10.0 (1.2–31.7)
Disease control rate, %77.475.0
Response duration1 L (n = 10)2 L (n = 2)
Median duration of response (95% CI), months9.9 (2.8–NE)NE (6.9–NE)
Proportion of patients with specified duration of response (95% CI), %c
 6 months60.0 (25.3–82.7)100.0 (NE)
 12 months30.0 (7.1–57.8)50.0 (0.6–91.0)

a Due to no postbaseline assessment (n = 2) or stable disease of insufficient duration (< 6 weeks after start date without further tumor assessment; n = 1)

b All postbaseline assessments not evaluable (n = 1)

c Based on Kaplan-Meier estimates

1 L first-line subgroup, 2 L second-line subgroup, CI confidence interval, NE not evaluable